- Home
- SWVL vs PEPG Comparison
SWVL vs PEPG Comparison
Compare SWVL & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- PEPG
- Stock Information
- Founded
- SWVL 2017
- PEPG 2018
- Country
- SWVL United Arab Emirates
- PEPG United States
- Employees
- SWVL N/A
- PEPG N/A
- Industry
- SWVL Business Services
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- SWVL Consumer Discretionary
- PEPG Health Care
- Exchange
- SWVL Nasdaq
- PEPG Nasdaq
- Market Cap
- SWVL 44.5M
- PEPG 45.5M
- IPO Year
- SWVL N/A
- PEPG 2022
- Fundamental
- Price
- SWVL $4.75
- PEPG $1.25
- Analyst Decision
- SWVL
- PEPG Buy
- Analyst Count
- SWVL 0
- PEPG 3
- Target Price
- SWVL N/A
- PEPG $7.67
- AVG Volume (30 Days)
- SWVL 22.5K
- PEPG 340.5K
- Earning Date
- SWVL 07-22-2025
- PEPG 08-07-2025
- Dividend Yield
- SWVL N/A
- PEPG N/A
- EPS Growth
- SWVL N/A
- PEPG N/A
- EPS
- SWVL N/A
- PEPG N/A
- Revenue
- SWVL $17,207,362.00
- PEPG N/A
- Revenue This Year
- SWVL N/A
- PEPG N/A
- Revenue Next Year
- SWVL N/A
- PEPG N/A
- P/E Ratio
- SWVL N/A
- PEPG N/A
- Revenue Growth
- SWVL N/A
- PEPG N/A
- 52 Week Low
- SWVL $2.40
- PEPG $0.88
- 52 Week High
- SWVL $8.05
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- SWVL 63.96
- PEPG 46.05
- Support Level
- SWVL $3.87
- PEPG $1.07
- Resistance Level
- SWVL $4.67
- PEPG $1.27
- Average True Range (ATR)
- SWVL 0.49
- PEPG 0.10
- MACD
- SWVL 0.04
- PEPG -0.00
- Stochastic Oscillator
- SWVL 95.45
- PEPG 45.45
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.